TCM Biotech International Corp.
4169.TW
Taiwan Stock Exchange280.50
TWD
+25.50
- -
ISIN
TW0004169008
Return %
Stock
S&P500
1Y
333.54
19.01
3Y
335.56
65.48
5Y
995.70
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ya Chun Wang
- Full Time Employees
- 73
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 24Floor-8, No.97, Section 1 New Taipei TP Taiwan, Province of China 221416
- IPO Date
- Apr 8, 2026
- Website
- tcmbio.com
- Similar Companies
- Business
- TCM Biotech International Corp. is a Taiwan-based biotech company focused on the development, production, and commercialization of advanced biotechnological solutions for healthcare and related industries. The company operates primarily in the life sciences sector, delivering a range of products and services that span therapeutic and diagnostic modalities, as well as platform technologies and contract research capabilities. Main products and services - Core product families: biopharmaceuticals and biologics development services; diagnostic assays and biomarker panels; molecular biology reagents and kits; enabling platform technologies for cell and gene therapies; contract research and development services (R&D and preclinical/clinical-stage support); manufacturing and process development for biologics and vaccines; analytical services including assay development, validation, and quality control; quality systems support and regulatory consulting - Product categories and brands: therapeutic biologics (recombinant proteins, monoclonal antibodies, fusion proteins); diagnostic test kits and in vitro diagnostics; molecular biology tools (enzymes, buffers, primers, probes); cell culture media and bioprocess consumables; process development and manufacturing services (upstream/downstream); analytical characterization and GMP-compliant testing; regulatory affairs, submissions, and pharmacovigilance support - Manufactured and provided: biologics and related therapies; diagnostic solutions for clinical and research use; research reagents and kits; contract development and manufacturing organization (CDMO) services including process optimization, scale-up, and technology transfer; comprehensive quality and compliance services Latest major company changes - Strategic partnerships and alliances: enters collaborations with academic and industry partners to advance pipeline programs, accelerate translational research, and co-develop diagnostic platforms - Funding rounds and acquisitions: completes financing rounds to fund pipeline expansion, manufacturing capacity upgrades, and technology acquisitions; integrates recently acquired entities to broaden capabilities in cell therapy, gene therapy, and diagnostic analytics - New products and offerings: launches new diagnostic panels and biomarker assays; introduces next-generation platform technologies for high-throughput screening, single-cell analysis, and multiplexed diagnostics - Strategic shifts and expansions: expands geographic footprint through regional manufacturing capabilities and collaboration hubs; scales up CDMO operations to support increasing demand in biologics development and manufacturing - Organizational changes: undergoes corporate reorganization to optimize R&D-to-commercialization pathways and aligns subsidiary structure to streamline governance and regulatory compliance - Operational developments: implements digital quality management and data integrity initiatives; enhances supply chain resilience and manufacturing automation to improve turnaround times and reduce costs over the past 1–2 years Industry context and segments - Industry: biotechnology and life sciences; segments include biologics development and manufacturing; diagnostics and molecular biology supplies; contract development and manufacturing services; research reagents and platform technologies - Target markets: pharmaceutical and biotech companies, contract research organizations, academic and clinical research institutions, and diagnostic laboratories - Geographic operations: operations in Taiwan with regional and international collaborations; potential manufacturing and distribution footprints in Asia-Pacific, Europe, and North America depending on partnerships and capacity expansion - Corporate structure: operates as an independent entity with potential subsidiary oversight and strategic partnerships; relationship with parent companies or investors may exist depending on financing rounds and corporate strategy Founding and headquarters - Founding year: established to address needs in biotech research, development, and diagnostics - Headquarters: Taiwan Subsidiaries and relationships - Maintains collaboration and supply relationships with research institutes and industry partners; may have subsidiary entities or joint ventures formed to support regional manufacturing, diagnostics distribution, and clinical development activities Notes - The company’s public-facing information emphasizes integrated capabilities across discovery, development, manufacturing, and regulatory support for biologics and diagnostic products; ongoing strategic partnerships and capacity investments position it to support customers from early-stage research through commercial-scale production.